Ikris Pharma

It has recently come to the surface that Erlotinib in a low dosage can be a safe alternative for elderly patients diagnosed with EGFR mutation-positive non-small cell lung cancer. A trial was conducted with a total number of 80 patients, of whom 54 were men. All of them had EGFR mutation-positive non-small cell lung cancer. They were given Erlotinib 50mg per day, which is considered to be a low dose, while the typical dosage is Erlotinib 100mg or Erlotinib 150 mg (maximum) each day. The test would be considered as successful if 60% of the participants had a positive response.

It is also required to mention here that the ages of the patients range between 49 to 90 years to confirm whether or not the low dosage Erlotinib for the treatment of non-small cell lung cancer is effective. Among them, most men were diagnosed at Stage IV or had a chronic condition.

The results of the study were promising, where it was revealed that 60% of the patients responded to the treatment. To be precise, there were 47 partial responses and 1 complete response. Mention may also be made of the fact that 24 patients had stable disease while 5 were dealing with progressive conditions.

The disease control rate came to a promising 90%. In fact, none of the patients died after the treatment. Nor did they develop any treatment-related interstitial drug disease. That being said, it is also essential to state that the treatment for 10 patients was suspended temporarily for adverse effects, the dosage for 5 patients had to be reduced to 25mg per day, and 2 of them had their treatment stopped permanently. The median progression-free survival came to be a total of 9.3 months, while the median overall survival was 26.2 months.

Read:- 17q22 loss Associated with Survival in Enzalutamide-Resistant mCRPC